Document:

Exhibit 10.2

 

NEITHER
THIS NOTE NOR THE SECURITIES UNDERLYING THIS NOTE, NOR ANY SECURITIES ISSUABLE UPON ITS CONVERSION, IF ANY, HAVE BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT’), OR QUALIFIED UNDER APPLICABLE STATE SECURITIES LAWS AND MAY ONLY BE ACQUIRED
FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION HEREOF OR THEREOF. NEITHER THIS
NOTE, NOR THE SECURITIES UNDERLYING THIS NOTE NOR ANY SECURITIES ISSUABLE UPON ITS CONVERSION, IF ANY, MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT AND QUALIFICATION UNDER
APPLICABLE STATE LAW WITHOUT AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION ARE NOT REQUIRED
UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.

 

BRAIN
SCIENTIFIC, INC. 

 

CONVERTIBLE
PROMISSORY NOTE

 

Dated:
October 1, 2021 (“Issuance Date”)

 

FOR
VALUE RECEIVED BRAIN SCIENTIFIC, INC., a company organized under the laws of the State of Nevada (the “Company”),
hereby promises to pay to [Holder] (the “Payee”), or its registered assigns, the principal amount of [Principal Amount]
($[Amount]USD) in accordance with the provisions of this Convertible Promissory Note (as amended, modified and supplemented from time
to time, this “Note” and together with all other Notes issued in the Note Issuance (as defined below) or upon transfer
or exchange, the “Notes”). Capitalized terms not defined in this Note shall have the meaning ascribed to them in the
Securities Purchase Agreement, dated as of October 1, 2021, among the Company and the purchasers party thereto (the “Purchase
Agreement”).

 

Certain
capitalized terms are defined in Section 9 hereof.

 

1. Interest
Rate. This Note bears an annualized interest rate of ten percent (10%) payable upon maturity or a conversion of the Note and shall
begin accruing on such date as the initial funds shall have been distributed pursuant to the terms of the Escrow Agreement. All interest
accruing hereunder shall be paid-in-kind on the last day of each calendar month by capitalizing and adding such amount to the outstanding
principal balance of this Note, which amount shall thereafter constitute principal hereunder.

 

2. Maturity
Date. The entire principal amount of this Note shall be due and payable on April 1, 2023 (such date, the “Maturity Date”).

 

     

     

    

 

3. Conversion.

 

(a)
Mandatory Conversion.

 

(i) This Note shall automatically convert into shares of Common Stock or Units, as provided herein, immediately upon the earliest to occur
of (a) the listing of the Common Stock on NASDAQ (the “Uplist”), and (b) a Subsequent Qualified Financing Date. For
purposes of this Note, a “Unit” shall mean the combination of Common Stock and warrants to purchase Common Stock offered
by the Company in any financing occurring simultaneously with the Uplist (“Simultaneous Uplist Unit Offering”). For
purposes of this Note, “Subsequent Qualified Financing Date” shall mean the date on which the Company shall have received
proceeds in excess of $5,000,000.00 from a transaction or series of related transactions occurring prior to the Maturity Date, including,
but not limited to, equity financings, business combinations or other issuances of the Company’s equity securities (not including
the transactions contemplated by the Purchase Agreement).

 

(ii) If this Note is being converted in connection with an Uplist, and no Simultaneous Uplist Unit Offering shall have occurred, this Note
shall be convertible into a number of shares of Common Stock equal to the quotient of (I) the outstanding aggregate principal amount
of this Note plus accrued but unpaid interest thereon, divided by (II) the lesser of (a) $0.90 and (b) the greater of (x) $0.20
and (y) eighty percent (80%) of closing price for the Common Stock on the Trading Day prior to the date of the Uplist.

 

(iii) If this Note is being converted in connection with an Uplist, and a Simultaneous Uplist Unit Offering shall have occurred, this Note
shall be convertible into a number of Units equal to the quotient of (I) the outstanding aggregate principal amount of this Note plus
accrued but unpaid interest thereon, divided by (II) the lesser of (a) $0.90 and (b) the greater of (x) $0.20 and (y) eighty percent
(80%) of the per Unit price in the Simultaneous Uplist Unit Offering,.

 

(iv) If this Note is being converted upon a Subsequent Qualified Financing Date, this Note shall be convertible into a number of shares
of Common Stock equal to the quotient of (I) the outstanding aggregate principal amount of the Note plus accrued but unpaid interest
thereon, divided by (II) the lesser of (a) $0.90 and (b) the greater of (x) $0.20 and (y) eighty percent (80%) of the VWAP for the Common
Stock for the five (5) consecutive Trading Days immediately preceding such Subsequent Qualified Financing Date.

 

(v)  In connection with any conversion of this Note pursuant to this Section 3(a), the Company will deliver a dated and signed notice
of conversion (the “Company Notice of Conversion”), the form of which is attached to this Note as Exhibit A-1,
notifying the Payee of the conversion.

 

(b)
Voluntary Conversion.

 

(i)
The Holder shall have the right (subject to the conversion limitations set forth in Section 3(c)(viii) hereof) from time following the
date hereof to convert all or any part of the outstanding and unpaid principal and interest under this Note into fully paid and non-assessable
shares of Common Stock, as such Common Stock exists on the date hereof, or any shares of capital stock or other securities of the Borrower
into which such Common Stock shall hereafter be changed or reclassified at the Voluntary Conversion Price (as defined below).

 

(ii) If
this Note is being converted pursuant to this Section 3(b), this Note shall be convertible into a number of shares of Common Stock equal
to the quotient of (I) the outstanding aggregate principal amount of the Note plus accrued but unpaid interest thereon, divided by (II)
the lesser of (a) $0.90 and (b) the greater of (x) $0.20 and (y) eighty percent (80%) of the VWAP for the Common Stock for the five (5)
consecutive Trading Days immediately preceding the applicable conversion date (the “Voluntary Conversion Price”).

 

    2

     

    

 

(iii) In
connection with any conversion of this Note pursuant to this Section 3(b), the Holder will deliver to the Company a dated and
signed notice of conversion (the “Holder Notice of Conversion”), the form of which is attached to this Note as Exhibit
A-2, notifying the Company of the proposed conversion. If no date of conversion is specified in a Holder Notice of Conversion, the
date of conversion shall be the date that such Holder Notice of Conversion is deemed delivered hereunder.

 

(c)
General Conversion Provisions.

 

(i) No
fractional shares shall be issued upon a conversion and all fractional shares shall be rounded up to the nearest whole share of Common
Stock.

 

(ii) As
soon as possible after a conversion has been effected (but in any event within five (5) Trading Days), the Company shall deliver to the
Payee a certificate or certificates representing the shares and warrants (in the case of any conversion of this Note into Units) issuable
by reason of such conversion in such name or names and such denomination or denominations as the then Payee has specified in writing
to the Company, or if not so specified, in one (1) certificate and in the name of the then Payee.

 

(iii) In
lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Company is participating
in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”) program, upon written request
of the then Payee and its compliance with the provisions contained in Section 1.1 and in this Section 3(xii), the Company shall use its
commercially reasonable best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion
to the Payee by crediting the account of such Payee’s broker with DTC through its Deposit Withdrawal At Custodian (“DWAC”)
system.

 

(iv) The
issuance of Common Stock or Units upon conversion of this Note shall be made without charge to the then Payee in respect thereof or other
cost incurred by the Company in connection with such conversion. Upon conversion of this Note, the Company shall take all such actions
as are necessary to ensure that the Common Stock or warrants (in the case of any conversion of this Note into Units) issuable upon conversion
of the Note shall be validly authorized and available for issue, fully paid and nonassessable.

 

(v) The
Company shall not close its books against the transfer of this Note in any manner which interferes with the timely conversion of this
Note. The Company shall assist and cooperate with any holder of this Note required to make any governmental filings or obtain any governmental
approval prior to or in connection with the conversion of this Note (including, without limitation, making any filings required to be
made by the Company).

 

(vi) The
Company shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose
of issuance upon conversion hereunder, such number of shares of Common Stock issuable upon conversion of this Note. All shares of Common
Stock issuable upon conversion of this Note shall, when issued, be duly and validly issued, fully paid and nonassessable and free from
all taxes, liens and charges other than those occurring as a result of the actions or non-actions of the holder. The Company shall take
all such actions as may be reasonably necessary to assure that all such shares of Common Stock may be so issued without violation of
any applicable law or governmental regulation or any requirements of the Trading Market for the Common Stock.

 

    3

     

    

 

(vii) The
shares of Common Stock or shares of Common Stock underlying warrants, if any (in the case of any conversion of this Note into Units)
issuable upon conversion of this Note may not be sold or transferred unless (a) such shares or shares underlying the warrants are sold
pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “1933 Act”) or (b) the
Company or its transfer agent shall have been furnished with an opinion of counsel reasonably acceptable to the Company to the effect
that the shares or shares underlying such warrants to be sold or transferred may be sold or transferred pursuant to an exemption from
such registration or (c) such shares or warrants are sold or transferred pursuant to Rule 144 of the 1933 Act, or other applicable exemption.
Until such time as the shares of Common Stock or shares underlying the warrants have been registered under the 1933 Act or otherwise
may be sold pursuant to Rule 144 or other applicable exemption without any restriction including as to the amount of securities as of
a particular date that can then be immediately sold, each certificate for shares of Common Stock or shares underlying warrants that is
not included in an effective registration statement or that have not been sold pursuant to an effective registration statement or an
exemption that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

 

“NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID
ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144, RULE 144A, REGULATION S UNDER SAID ACT, OR OTHER APPLICABLE EXEMPTION.”

 

    4

     

    

 

(viii) The
Company shall not effect any conversion of principal and/or interest of this Note, and a Holder shall not have the right to the conversion
of any principal and/or interest of this Note, to the extent that after giving effect to the conversion set forth on the applicable Notice
of Conversion, the Holder (together with the Holder’s affiliates, and any persons acting as a group together with the Holder or
any of the Holder’s affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For
purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its affiliates shall include
the number of shares of Common Stock issuable upon conversion of this Note with respect to which such determination is being made, but
shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted principal amount
of this Note beneficially owned by the Holder or any of its affiliates and (ii) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company subject to a limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by the Holder or any of its affiliates. Except as set forth in the preceding sentence, for purposes of this
Section 3(c)(viii), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Upon the written or oral request of a Holder,
the Company shall within two Business Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Note, by the Holder or its affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of this Note
held by the Holder. The Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 3(c)(viii), provided that the Beneficial Ownership Limitation in no event exceeds 9.99%
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
conversion of this Note held by the Holder and the Beneficial Ownership Limitation provisions of this Section 3(c)(viii), shall continue
to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Company. The Beneficial
Ownership Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 3(c)(viii), to correct this paragraph (or any portion hereof) which may be defective or inconsistent with
the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Note.

 

4. Method
of Payments.

 

(i) Payment.
So long as the Payee or any of its registered assigns shall be the holder of this Note, and if this Note has not previously been converted,
the Company will pay all outstanding principal and accrued but unpaid interest becoming due on this Note held by the Payee or any of
its registered assigns not later than 1:00 p.m. New York time, on the date such payment is due hereunder, in immediately available funds,
in accordance with the payment instructions attached hereto on Schedule 4(i), without the presentation or surrender of this Note
or the making of any notation thereon. Any payment made after 4:00 p.m. New York time, on a Business Day will be deemed made on the next
following Business Day. If the due date of any payment in respect of this Note would otherwise fall on a day that is not a Business Day,
such due date shall be extended to the next succeeding Business Day. All amounts payable under this Note shall be paid free and clear
of, and without reduction by reason of, any deduction, set-off or counterclaim. The Company will afford the benefits of this Section
to the Payee and to each other Person holding this Note.

 

(ii) Transfer
and Exchange. Upon surrender of any Note for registration of transfer or for exchange to the Company, in accordance with the terms
hereof, at its principal office, the Company at its sole expense will execute and deliver in exchange therefor a new Note or Notes, as
the case may be, as requested by the holder or transferee, which aggregate principal amount is equal to the unpaid principal amount of
such Note, registered as such holder or transferee may request; provided that this Note may not be transferred by Payee to any Person
other than Payee’s affiliates without the prior written consent of the Company (which consent shall not be unreasonably withheld
or delayed). The issuance of new Notes shall be made without charge to the holder(s) of the surrendered Note for any issuance tax in
respect thereof or other cost incurred by the Company in connection with such issuance, provided that each Noteholder shall pay any transfer
taxes associated therewith. The Company shall be entitled to regard the registered holder of this Note as the holder of the Note so registered
for all purposes until the Company or its agent, as applicable, is required to record a transfer of this Note on its register.

 

    5

     

    

 

(iii) Replacement.
Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of any Note and, in the
case of any such loss, theft or destruction of any Note, upon receipt of an indemnity reasonably satisfactory to the Company or, in the
case of any such mutilation, upon the surrender and cancellation of such Note, the Company, at its expense, will execute and deliver,
in lieu thereof, a new Note of like tenor and dated the date of such lost, stolen, destroyed or mutilated Note.

 

5. Redemption.
Prior to the date of any Uplist or the Maturity Date, this Note may be redeemed in full by the Company following three (3) days’
notice to the Payee, by paying in full the then outstanding principal amount plus any accrued but unpaid interest owing hereunder without
any premium or other payment.

 

6. Covenants
of the Company. The Company covenants and agrees as follows:

 

(i) Use
of Proceeds. The Company shall use the net proceeds received in the Offering only for working capital purposes and not to redeem
or make any payment on account of any securities of the Company other than as provided in Schedule 1 attached hereto.

 

(ii) Notes.
All Notes issued under the Purchase Agreement shall be on the same terms and shall be in substantially the same form as this Note. All
cash payments to the holder of any Note shall be made to all holders of Notes, pro rata, based on the outstanding aggregate principal
amount of each such holder’s Note to the aggregate principal amount of all Notes outstanding at such time.

 

7. Events
of Default. If any of the following events take place before or on the Maturity Date or the date of full conversion of this Note
(each, an “Event of Default”), holders owning 50.1% of the aggregate principal amount of all Notes then outstanding
may declare an Event of Default by providing written notice thereof to the Company, all outstanding aggregate principal and accrued but
unpaid interest on this Note and the other Notes outstanding immediately due and payable; provided, however, that this
Note shall automatically become due and payable:

 

(i) Company
fails to make payment of the full amount due under this Note upon the tender of such Note following the Maturity Date, which failure
to make payment continues for a period of five (5) days after receipt by the Company of written notice from the Noteholder of such default;
or

 

(ii) Company
files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief
of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate
action in furtherance of any of the foregoing;

 

(iii) An
involuntary petition is filed against the Company (unless such petition is dismissed or discharged within sixty (60) days) under any
bankruptcy statute then in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar person)
is appointed to take possession, custody or control of any property of the Company;

 

(iv) Company
dissolves, liquidates or ceases business activity, or transfers any major portion of its assets other than in the ordinary course of
business; provided that this paragraph (ix) shall not apply to any contemplated real estate transaction; or

 

    6

     

    

 

(v) Company
breaches any material covenant or agreement on its part contained herein and such breach has not been remedied within twenty (20) days
after receipt by the Company of written notice from the Noteholder of such breach.

 

8. Definitions.

 

“Business
Day” means a day (other than a Saturday or Sunday) on which banks generally are open in New York, New York for the conduct
of substantially all of their activities.

 

“Common
Stock” means the Company’s common stock, par value $0.001 per share.

 

“Noteholder”
or “Payee” with respect to any Note including this Note, means at any time each Person then the record owner thereof
and “Noteholders” or “Payees” means all of such Noteholders or Payees, collectively.

 

“Note
Issuance” or “Offering” shall mean the private placement by the Company of its 10% Convertible Promissory
Notes issued by the Company to the Payee and other purchasers of Notes (each Note in substantially the form of this Note) in the original
principal amount not to exceed $______ in the aggregate.

 

“Person”
means any person or entity of any nature whatsoever, specifically including an individual, a firm, a company, a corporation, a partnership,
a limited liability company, a trust or other entity.

 

“Trading
Day” means any day that shares of Common Stock are traded on the  Trading Market.

 

“Trading
Market” shall mean the principal securities exchange or trading market where the  Common Stock is listed or traded, including
but not limited to any tier of the OTC Markets, any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the New York Stock
Exchange, or the NYSE American, or any successor to such markets.

 

“VWAP” means,
for any Trading Day, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such Trading Day (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets”
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected by mutual agreement of the Company and Noteholders owning no less than 50.1% of the
then aggregate principal amount of the Notes outstanding.

 

    7

     

    

 

9. Expenses
of Enforcement, etc. The Company agrees to pay all reasonable fees and expenses incurred by the Payee in connection with any amendments,
modifications, waivers, extensions, renewals, renegotiations or “workouts” of the provisions hereof or incurred by the Payee
in connection with the enforcement or protection of its rights in connection with this Note, or in connection with any pending or threatened
action, proceeding, or investigation relating to the foregoing, including but not limited to the reasonable fees and disbursements of
one (1) legal counsel that represents all Noteholders (“Fees and Expenses”). The Company indemnifies the Payee and its directors,
managers, affiliates, partners, members, officers, employees and agents against, and agrees to hold the Payee and each such person and/or
entity harmless from, any and all losses, claims, damages, liabilities and related expenses, including reasonable counsel fees and expenses,
incurred by or asserted against the Payee or any such person and/or entity arising out of, in any way connected with, or as a result
of the consummation of the loan evidenced by this Note and the use of the proceeds thereof or any claim, litigation, investigation or
proceedings relating to any of the foregoing, whether or not the Payee or any such person and/or entity is a party thereto other than
any loss, claim, damage, liability or related expense incurred or asserted against the payee or any such person on account of the payee’s
or such person’s gross negligence or willful misconduct. Notwithstanding the foregoing, with respect to the indemnification obligations
of the Company hereunder, (i) the Company’s aggregate liability under this Note to the Payee shall not exceed the outstanding aggregate
principal amount of this Note (this limitation does not apply to Fees and Expenses), and (ii) indemnified liabilities shall not include
any liability of any indemnitee arising out of such indemnitee’s gross negligence or willful or intentional misconduct. To the
extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution
to the payment and satisfaction of each of the indemnified liabilities which is permissible under applicable law.

 

10. Amendment
and Waiver. The provisions of this Note may only be modified, amended or waived by the written consent of the Company and the holder
or, whether or not agreed to by the holder, with the written consent of the Company and holders of a majority of the aggregate principal
amount of all Notes then outstanding.

 

11. Remedies
Cumulative. No remedy herein conferred upon the Payee is intended to be exclusive of any other remedy and each and every such remedy
shall be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law or in equity or
by statute or otherwise.

 

12. Remedies
Not Waived. No course of dealing between the Company and the Payee or any delay on the part of the Payee in exercising any rights
hereunder shall operate as a waiver of any right of the Payee.

 

13. Assignments.
The Payee may assign, participate, transfer or otherwise convey this Note and any of its rights or obligations hereunder to any affiliate
of Payee and to any other Person that the Company consents to (such consent not to be unreasonably withheld or delayed), and this Note
shall inure to the benefit of the Payee’s successors and permitted assigns. The Company shall not assign or delegate this Note
or any of its liabilities or obligations hereunder.

 

14. Headings.
The headings of the sections and paragraphs of this Note are inserted for convenience only and do not constitute a part of this Note.

 

15. Severability.
If any provision of this Note is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this
Note will remain in full force and effect. Any provision of this Note held invalid or unenforceable only in part or degree will remain
in full force and effect to the extent not held invalid or unenforceable.

 

    8

     

    

 

16. Cancellation.
After all principal, premiums (if any) at any time owed on this Note have been paid in full, or this Note has been converted this
Note will be surrendered to the Company for cancellation and will not be reissued.

 

17. Governing
Law; Jurisdiction. This Note and the terms and conditions set forth herein, shall be governed by and construed solely and exclusively
in accordance with the internal laws of the State of New York without regard to the conflicts of laws principles thereof. The parties
hereto hereby expressly and irrevocably agree that any suit or proceeding arising directly and/or indirectly pursuant to or under this
Note shall be brought solely in a federal or state court located in the City, County and State of New York. By its execution hereof,
the parties hereto covenant and irrevocably submit to the in personam jurisdiction of the federal and state courts located in the City,
County and State of New York and agree that any process in any such action may be served upon any of them personally, or by certified
mail or registered mail upon them or their agent, return receipt requested, with the same full force and effect as if personally served
upon them in New York, New York. The parties hereto expressly and irrevocably waive any claim that any such jurisdiction is not a convenient
forum for any such suit or proceeding and any defense or lack of in personam jurisdiction with respect thereto. In the event of any such
action or proceeding, the party prevailing therein shall be entitled to payment from the other parties hereto of all of its reasonable
counsel fees and disbursements.

 

18. Maximum
Legal Rate. If at any time an interest rate applicable hereunder exceeds the maximum rate permitted by law, such rate shall be reduced
to the maximum rate so permitted by law.

 

19. Place
of Payment. Unless otherwise stated herein, payments of principal and interest shall be delivered to the holder of this Note at the
address provided by the Payee in the Purchase Agreement, or at such other address as such Noteholder has specified by prior written notice
to the Company.

 

20. Notice.
Where this Note provides for notice of any event or otherwise, such notice shall be given (unless otherwise herein expressly provided)
in writing and either (a) delivered personally, (b) sent by certified, registered or express mail, postage prepaid or (c) sent by facsimile
or other electronic transmission, and shall be deemed given when so delivered personally, sent by facsimile or other electronic transmission
(confirmed in writing) or mailed. Notices shall be addressed, if to the Company, to its then principal office, or if to the Holder, to
its address as provided in the Purchase Agreement or such other address as may be specified by the Holder in a written notice delivered
to the Company under this Section 20.

 

21. WAIVER
OF JURY TRIAL. THE PAYEE AND THE COMPANY EACH HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE AND/OR THE TRANSACTIONS CONTEMPLATED HEREUNDER.

 

22. No
Recourse Against Others. The obligations of the Company under this Note are solely obligations of the Company and no officer, employee,
stockholder or director of the Company shall be liable for any failure by the Company to pay amounts on this Note when due or perform
any other obligation.

 

**********************************************

 

    9

     

    

 

IN
WITNESS WHEREOF, the Company has executed and delivered this Promissory Note on the date first written above.

 

	 	COMPANY:
	 	 	 
	 	BRAIN
    SCIENTIFIC, INC.
	 	 	 
	 	By:	 
	 	Name:	       
	 	Title:	 

 

ACCEPTED
AND AGREED TO BY PAYEE 

ON
THE DATE FIRST WRITTEN ABOVE

 

	 	 
	Print Name of Payee	 
	 	 
	 	 
	Signature	 

 

     

     

    

 

EXHIBIT
A-1

 

COMPANY
NOTICE OF CONVERSION

 

[Payee]

[Address]

 

Brain
Scientific, Inc. (the “Company”), the issuer of that certain 10% Convertible Promissory Note, issued on September
9, 2021 (the “Note”), hereby notifies you as holder of such Note that in accordance with Section 3(a) thereof the
outstanding principal balance of the Note plus accrued but unpaid interest thereon in the aggregate amount of $   will be
converted into [_______ shares of common stock, par value $0.001 of the Company][Units of the Company consisting of [_______ ] shares
of common stock, par value $0.001, and warrants entitling you to purchase [_______ ] shares of common stock, par value $0.001 at a per
share price of $__ and expiring on [date]] and issued to you in satisfaction in full of all amounts owing under the Note. Upon receipt
of such [shares][Units] (including in book-entry form at the Company’s transfer agent), the Note shall be cancelled.

 

Dated:
/ / 20 

 

	Brain Scientific, Inc. 	 
	 	 	 
	By:	 	 
	Name:	  	 
	Title:	 	 

 

     

     

    

 

EXHIBIT
A-2

 

HOLDER
NOTICE OF CONVERSION

 

Brain
Scientific, Inc.

6700
Professional Parkway

Lakewood
Ranch, Florida

Attention:
Bonnie-Jeanne Gerety

Email:
Bjgerety@piezomotion.com

 

The
undersigned, _______________, as holder of that certain 10% Convertible Promissory Note, issued by Brain Scientific, Inc. (the “Company”)
on September __, 2021 (the “Note”), hereby notifies the Company that in accordance with Section 3(b) thereof, that
it wishes to convert $________ of the outstanding principal balance of the Note and $________ of accrued but unpaid interest thereon,
into _______ shares of common stock, par value $0.001 of the Company, at a per share price of $______ , in satisfaction of such amount
owing under the Note. Upon receipt of such shares (including in book-entry form at the Company’s transfer agent), the portion of
the Note being so converted shall be cancelled.

 

Dated:
/ / 20 

 

	By:	 	 
	Name:	 	 
	Title:Exhibit 10.3

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This Executive
Employment Agreement (the “Agreement”) is made and entered into this 1st day of October, 2021, by and between
Brain Scientific Inc. (together with any and all parent and subsidiary entities, “Company”) and Hassan Kotob
(“Executive”).

 

WHEREAS, Executive and Piezo
Motion Corp. (“Piezo”) entered into that certain Executive Employment Agreement dated as of April 30, 2020 (the “Original
Employment Agreement”);

 

WHEREAS, on June 11, 2021
Company entered into an Agreement and Plan of Merger and Reorganization with Piezo and BRSF Acquisition Inc., a wholly-owned subsidiary
of Company (“Merger Sub”) pursuant to which Merger Sub will be merged with and into Piezo, Merger Sub will cease to
exist and Piezo will survive as a wholly-owned subsidiary of Company (the “Merger”); and

 

WHEREAS, as a condition to
and contemporaneous with the consummation of the Merger, (a) Executive and Piezo wish to terminate the Original Employment Agreement and
(b) Executive and Company wish to enter into an employment agreement such that Executive shall serve as the Executive Chair and Chief
Executive Officer of Company in accordance with the terms and conditions stated below;

 

NOW, THEREFORE, in consideration
of the mutual promises, terms, provisions, and conditions contained herein, the parties agree as follows:

 

1.
Title; Role; Duties.

 

(a) Subject
to the terms and conditions of this Agreement, Company shall employ Executive as its Executive Chairman and CEO and appoint Executive
to the Board of Directors of Company (“Board”) beginning on the Commencement Date described in Section 2 of this Agreement.
Executive accepts such employment and appointment upon the terms and conditions set forth herein. Executive agrees to endeavor to fulfill
and satisfy the duties and responsibilities that are customary for such position taking into consideration the size of Company, the industry
and location in which Company operates and such other applicable conditions. During Executive’s employment, Executive shall devote
the majority of Executive’s business time, energies and efforts to the business and affairs of Company, and shall act in conformity
in all material respects with the written policies and as the Board reasonably directs at all times. For the avoidance of doubt, Executive
may (i) serve on corporate boards (or other similar governing bodies of other business enterprises or organizations), (ii) serve on corporate,
industry or governmental advisory boards (or other similar consultative or advisory bodies), (iii) serve on civic, political or charitable
boards (or similar governing bodies) or engage in civic, charitable or political activities, and (iv) manage his personal investments,
and serve as an executor, trustee, or in a similar fiduciary capacity in connection therewith, provided in each case that such activities
do not, individually or in the aggregate, materially conflict or interfere with the performance of Executive’s duties under this
Agreement. Executive shall be permitted to work and provide services in such locations as he deems appropriate, including in the Miami,
FL vicinity.

 

(b) Executive shall serve
as a member of the Board of Directors of Company (including, for the avoidance of doubt, all subsidiaries of Brain Scientific Inc.) for
so long as he either is employed by Company (including, for the avoidance of doubt, employment by any subsidiary of Brain Scientific Inc.)
or owns 2% or more of the outstanding equity of the Brain Scientific Inc.  

 

     

     

    

 

2. Term
of Employment.

 

(a) Term.
Subject to the terms hereof, Executive’s employment hereunder shall commence on or before September 10, 2021 (the “Commencement
Date”), and shall continue until terminated hereunder by either party.

 

(b) Termination.
Notwithstanding anything else contained in this Agreement, Executive’s employment hereunder shall terminate upon the earliest to
occur of the following:

 

(i) Death.
Immediately upon Executive’s death.

 

(ii) Termination
by Company.

 

(A) If
because of Executive’s Disability (as defined in Section 2(c) below), upon written notice by Company to Executive that Executive’s
employment is being terminated as a result of Executive’s Disability, which termination shall be effective on the date of such notice
or such later date as specified in writing by Company;

 

(B) If
for Cause (as defined in Section 2(d) below), upon written notice by Company to Executive that Executive’s employment is being terminated
for Cause and that sets forth the factual basis supporting the alleged Cause, which termination shall be effective on the latest of the
date of such notice, the end of the applicable cure period, as set forth in Section 2(d) below, or such later date as specified in writing
by Company; provided that if Executive has cured the circumstances giving rise to Cause as set forth in Section 2(d) below, then
such termination shall not be effective; or

 

(C) If
by Company for reasons other than Disability or Cause, upon written notice by Company to Executive that Executive’s employment is
being terminated, which termination shall be effective on the date of such notice or such later date as specified in writing by Company.

 

(iii) Termination
by Executive.

 

(A) If
for Good Reason (as defined in Section 2(e) below), upon written notice by Executive to Company that Executive is terminating Executive’s
employment for Good Reason and that sets forth the factual basis supporting the alleged Good Reason, which termination shall be effective
on the date of such notice or such later date as specified in writing by Executive; or

 

(B) If
without Good Reason, written notice by Executive to Company that Executive is terminating Executive’s employment, which termination
shall be effective at least ten (10) days after the date of such notice; provided that Executive and Company may agree upon an
earlier effective date.

 

(c) Definition
of “Disability”. For purposes of this Agreement, “Disability” shall mean Executive’s incapacity
or inability to perform Executive’s duties and responsibilities as contemplated herein for a continuous period of at least one hundred
eighty (180) days because Executive’s physical or mental health has become so impaired as to make it impossible or impractical even
with reasonable accommodation for Executive to perform the duties and responsibilities contemplated hereunder.

 

    2

     

    

 

(d) Definition
of “Cause”. As used herein, “Cause” shall mean: (i) Executive’s engagement in willful misconduct
or gross negligence in connection with the performance of his material duties hereunder, which, in each case, is materially injurious
to Company; (ii) Executive’s conviction (after the exhaustion of all available appeals) of (A) any felony or (B) any crime involving
embezzlement, knowing misappropriation of funds, or fraud with respect to Company or otherwise in his capacity as an employee of Company
or member of the Board; (iii) Executive’s material breach of the Confidentiality Agreement (as defined below) or similar written
agreement enter into by Executive and Company; or (iv) Executive’s material breach of this Agreement; provided that if the
circumstance(s) in subsection (i), (iii), or (iv) is (or are) capable of being cured, Company has first provided Executive with written
notice setting forth in reasonable detail the circumstance(s) that Company alleges constitute(s) “Cause” and Executive has
failed to cure such circumstance(s) within a period of thirty (30) days after the date of receipt of such written notice.

 

(e) Definition
of “Good Reason”. As used herein, “Good Reason” shall mean the occurrence of any of the following conditions
without Executive’s written consent: (i) a relocation of Executive’s principal business location to a location more than twenty
(20) miles from Executive’s then-current business location; (ii) a material diminution in Executive’s title, duties, authority
or responsibilities; (iii) a reduction in Executive’s Base Salary; (iv) a material diminution of Executive’s benefits as in
effect at any point in time; (iv) any requirement that Executive report to any supervisor other than the Board; (v) a material diminution
in the budget over which Executive retains authority; or (vi) a material breach by Company of this Agreement or any other written agreement
between Executive and Company. For purposes of clarification, the above-listed conditions shall apply separately to each occurrence of
Good Reason, and failure to adhere to such conditions in the event of Good Reason shall not disqualify Executive from asserting Good Reason
for any subsequent occurrence of Good Reason.

 

3. Compensation.

 

(a) Base
Salary. Company shall pay Executive a base salary (the “Base Salary”) at the annual rate of three hundred and ninety
thousand dollars ($390,000.00). The Base Salary shall be payable in substantially equal periodic installments in accordance with Company’s
payroll practices as in effect from time to time. Company shall deduct from each such installment all amounts required to be deducted
or withheld under applicable law or under any employee benefit plan in which Executive participates. The Board or an appropriate committee
thereof shall review the Base Salary at least annually and may increase, but not decrease, the Base Salary, and the Base Salary shall
be adjusted so as to maintain a positive difference of not less than 115% of the base salary of any other employee, officer, or consultant
of Company.

 

(b) Annual Bonus. Executive
shall be eligible to receive an annual bonus, which shall be payable in cash or equity as Executive and the Board mutually agree (the
“Annual Bonus”). The amount and milestones for each year’s Annual Bonus shall be agreed to by Executive and the
Board (or an appropriate committee thereof) no later than thirty (30) days prior to the beginning of the applicable year (or such later
time as Company and Executive mutually agree in writing); and upon achievement of the milestones, the Annual Bonus shall be at least
 two hundred fifty thousand dollars ($250,000). The Annual Bonus shall be paid to Executive as soon as administratively practicable
after the end of, but in no event later than March 15th of the calendar year immediately following, the calendar year in which
it was earned. Company shall deduct from the Annual Bonus all amounts required to be deducted or withheld under applicable law or under
any employee benefit plan in which Executive participates. For the current calendar year, Executive shall be eligible for the full amount
of the Annual Bonus taking into account services rendered to Piezo prior to the Commencement Date, subject to the terms and conditions
described above.

 

    3

     

    

 

(c) [RESERVED]

 

(d) Paid
Time Off. Executive shall be entitled to an annual paid vacation of five weeks each year, accruing monthly on a pro rata basis (or
any greater number of days offered generally to executives of Company). Executive also shall be entitled to customary sick and personal
leave time in accordance with Company policies then in effect, as may be amended from time to time.

 

(e) Benefits.
Executive shall be entitled to participate in all benefit/welfare plans and fringe benefits provided to senior executives or Company,
if and when Company offers such plans and benefits, subject to the terms of each applicable plan. Company shall not amend, modify or discontinue
any benefit plans or fringe benefits without written approval of Executive or as may be required by applicable law. If Company does not
have provide health benefits, long-term disability, short-term disability and/or life insurance (such life insurance to be in an amount
of at least $5,000,000), Company shall reimburse Executive for the reasonable expenses Executive incurs in obtaining such benefits personally.
Additionally, the Company shall reimburse you for the reasonable expenses incurred in connection with your obtaining an executive physical
examination on an annual basis.

 

(f) Reimbursement
of Expenses. Company shall reimburse Executive for all ordinary and reasonable out-of-pocket business expenses incurred by Executive
in furtherance of Company’s business in accordance with Company’s policies with respect thereto as in effect from time to
time. Such business expenses shall include reimbursement of payments of rent and associated office expenses in connection with Executive
maintaining an office for Company in the region of Miami, Florida. Executive shall be entitled to travel in business class. Company shall
reimburse Executive for all reasonable costs and expenses he incurs that are associated with his involvement with Company, including without
limitation any associated legal and accounting costs and expenses. Executive must submit any request for reimbursement no later than ninety
(90) days following the date that such business expense is incurred.

 

(g) Indemnification.
Executive shall be entitled to indemnification with respect to Executive’s services to Company pursuant to applicable law, the By-Laws
and charter of Company, and any applicable directors and officers (“D&O”) liability insurance policy of Company.
If not already obtained as of the date hereof, Company shall obtain, within thirty (30) days of the date hereof, from financially sound
and reputable insurers D&O liability insurance policy in an amount of at least $10,000,000 and on terms and conditions satisfactory
to Executive and shall use commercially reasonable efforts to cause such insurance policy to be maintained until such time as Executive
agrees in writing that such insurance should be discontinued. If any such D&O liability insurance policy is terminated, lapses or
is not renewed for any reason, Company shall notify Executive in writing promptly (and in any event within two business days). If Executive
is not already a party to an indemnification agreement with Company, Company and Executive shall enter into an Indemnification Agreement
in the form attached to this Agreement as Exhibit A.

 

    4

     

    

 

(h) Information
Rights. For so long as Executive owns 2% or more of the outstanding equity of Company, Company shall deliver to Executive:

 

		(i)	within one hundred twenty (120) days after the end of each fiscal year of Company (A) a consolidated balance sheet as of the end of
such year, (B) consolidated statements of income and of cash flows for such year, and a comparison between (1) the actual amounts as of
and for such fiscal year and (2) the comparable amounts for the prior year and as included in the Budget (as defined below) for such year,
with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such
year, and (3) a statement of stockholders’ equity as of the end of such year;

 

		(ii)	within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of Company, consolidated unaudited
statements of income and cash flows for such fiscal quarter, and an unaudited consolidated balance sheet and a statement of stockholders’
equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such
financial statements may (A) be subject to normal year-end audit adjustments; and (B) not contain all notes thereto that may be required
in accordance with GAAP);

 

		(iii)	within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of Company, a statement showing
the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock
outstanding at the end of the period, the common stock issuable upon conversion or exercise of any outstanding securities convertible
or exercisable for common stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock
options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit Executive to calculate
his percentage equity ownership in Company; and

 

		(iv)	no later than thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively,
the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow
for such months and, promptly after prepared, any other budgets or revised budgets prepared by Company.

 

Notwithstanding the foregoing, if any investor in or lender to Company
obtains rights to receive information about Company that are more expansive or on terms more favorable to the recipient than the above,
then Executive shall have the option in his sole discretion to receive the same such other information rights without regard to any status
as a “Major Investor” or any other conditions, whether based on threshold shareholdings or otherwise.

 

    5

     

    

 

4. Payments
upon Termination.

 

(a) Definition
of Accrued Obligations. For purposes of this Agreement, “Accrued Obligations” means the portion of Executive’s
Base Salary that has accrued prior to any termination of Executive’s employment with Company and has not yet been paid, any Annual
Bonus previously earned by Executive but not yet paid, any accrued and unused vacation or sick or personal leave, and the amount of any
expenses properly incurred by Executive on behalf of Company prior to any such termination and not yet reimbursed. Executive’s entitlement
to any other compensation or benefit under any plan of Company shall be governed by and determined in accordance with the terms of such
plans, except as otherwise specified in this Agreement.

 

(b) Termination
by Company for Cause, by Executive without Good Reason, or as a Result of Executive’s Disability or Death. If Executive’s
employment hereunder is terminated by Company for Cause, by Executive without Good Reason, or as a result of Executive’s Disability
or death, then Company shall pay the Accrued Obligations to Executive promptly following the effective date of such termination and shall
not be eligible for payments or benefits described in Section 4(c) below.

 

(c) Termination
by Company without Cause or by Executive For Good Reason. In the event that Executive’s employment is terminated by action of
Company other than for Cause, Disability or death, or Executive terminates Executive’s employment for Good Reason, then, in addition
to the Accrued Obligations, Executive shall receive the following:

 

(i) Severance
Payments. Payment in an amount equal to Executive’s then-current Base Salary until such date that is the later of the (A) three
(3) year anniversary of the date of the Commencement Date and (b) twelve (12) month anniversary of the effective date of such termination
(the “Continuation Period”), less customary and required taxes and employment-related deductions, paid in one lump
sum amount within thirty (30) days following the effective date of termination from employment, provided that if the 30th day falls
in the calendar year following the year during which the termination or separation from service occurred, then the payment shall be made
in such subsequent calendar year.

 

(ii) Severance
Bonus. Payment of a severance bonus in an amount equal to a pro rata portion of the target Annual Bonus to which Executive may have
been entitled for the year in which Executive’s employment terminates, less customary and required taxes and employment-related
deductions, paid in one lump sum amount within thirty (30) days following the effective date of termination from employment, provided
that if the 30th day falls in the calendar year following the year during which the termination or separation from service occurred, then
the payment shall be made in such subsequent calendar year.

 

(iii) Acceleration
of Vesting. All stock options, restricted stock and other equity issued or granted to, or purchased by, Executive that were subject
to vesting shall immediately and automatically become fully vested and immediately exercisable.

 

(iv) Benefits
Payments. Upon completion of appropriate forms and subject to applicable terms and conditions under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”), Company shall continue to provide Executive health insurance coverage
at no cost to Executive, until the earlier to occur of (A) the last day of the Continuation Period or (B) the date Executive elects to
participate in the group health plan of another employer. Subject to Company’s obligation under COBRA to provide timely notice,
Executive shall bear responsibility for applying for COBRA continuation coverage.

 

    6

     

    

 

(d) Release
Agreement. Company shall not be obligated to pay Executive the severance payments or benefits described in this Section 4 unless Executive
has executed, no later than sixty (60) days following Executive’s separation from service, a release agreement in substantially
the form attached hereto as Exhibit B.

 

(e) COBRA.
If the payment of any COBRA or health insurance premiums by Company on behalf of Executive as described herein would otherwise violate
any applicable nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable
Care Act of 2010, together with the Health Care and Education Reconciliation Act of 2010 (collectively, the “Act”)
or Section 105(h) of the Code, the COBRA premiums paid by Company shall be treated as taxable payments (subject to customary and required
taxes and employment-related deductions) and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory
treatment or taxation under the Act or Section 105(h) of the Code. If Company determines in its sole discretion that it cannot provide
the COBRA benefits described herein under Company’s health insurance plan without potentially violating applicable law (including,
without limitation, Section 2716 of the Public Health Service Act), Company shall in lieu thereof provide to Executive a taxable lump-sum
payment in an amount equal to the sum of the monthly (or then remaining) COBRA premiums that Executive would be required to pay to maintain
Executive’s group health insurance coverage in effect on the separation date for the remaining portion of the period for which Executive
shall receive the payments described in Section 4(b) or 4(c) above.

 

5. Confidentiality;
Inventions Assignment. In light of the competitive and proprietary aspects of the business of Company, and as a condition of employment
hereunder, Company and Executive shall enter into a Confidentiality and Inventions Assignment Agreement in the form attached to this Agreement
as Exhibit C.

 

6. Property
and Records. Upon the termination of Executive’s employment hereunder, or if Company otherwise requests in writing, Executive
shall: (i) return to Company all tangible business information and copies thereof, and (ii) deliver to Company any property of Company
which may be in Executive’s possession, including, but not limited to, cell phones, smart phones, laptops, products, materials,
memoranda, notes, records, reports or other documents or photocopies of the same; provided, however, that the provisions
of this Section 6 will not prohibit (A) retention of any documents relating to Executive’s compensation, benefits from
or ongoing obligations to Company or any of its affiliates, including this Agreement and any exhibits, appendices or attachments, or (B)
copies of any information reasonably required for tax preparation purposes and copies of any contacts, calendars and personal correspondence.

 

7. Taxation.

 

(a) The
intent of the parties is that payments and benefits under this Agreement comply with or otherwise be exempt from Section 409A of
the Code (“Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement will be interpreted to
be either exempt from or in compliance therewith, so that it shall not cause adverse tax consequences for Executive with respect to Section
409A, and any successor statute, regulation and guidance thereto. Executive acknowledges and agrees that Company does not guarantee the
tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences
related to Section 409A.

 

    7

     

    

 

(b) In
the event that the payments or benefits set forth in Section 4 of this Agreement constitute “non-qualified deferred compensation”
subject to Section 409A, then the following conditions apply to such payments or benefits:

 

(i) Any
termination of Executive’s employment triggering payment of benefits under Section 4 of this Agreement must constitute a “separation
from service” under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits
can commence. To the extent that the termination of Executive’s employment does not constitute a separation of service under Section
409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to be
provided by Executive to Company at the time Executive’s employment terminates), any such payments under Section 4 of this Agreement
that constitute deferred compensation under Section 409A shall be delayed until after the date of a subsequent event constituting a separation
of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes of clarification, this Section 7(b)
shall not cause any forfeiture of benefits on Executive’s part, but shall only act as a delay until such time as a “separation
from service” occurs.

 

(ii) Notwithstanding
any other provision with respect to the timing of payments under Section 4 of this Agreement if, at the time of Executive’s termination,
Executive is deemed to be a “specified employee” of Company (within the meaning of Section 409A(a)(2)(B)(i) of the Code),
then limited only to the extent necessary to comply with the requirements of Section 409A, any payments to which Executive may become
entitled under Section 4 of this Agreement which are subject to Section 409A (and not otherwise exempt from its application) shall be
withheld until the first (1st) business day of the seventh (7th) month following the termination of Executive’s
employment, at which time Executive shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to
Executive under the terms of Section 4 of this Agreement.

 

(c) It
is intended that each installment of the payments and benefits provided under Section 4 of this Agreement shall be treated as a separate
“payment” for purposes of Section 409A. Neither Company nor Executive shall have the right to accelerate or defer the delivery
of any such payments or benefits except to the extent specifically permitted or required by Section 409A. Notwithstanding any other provision
of this Agreement to the contrary, this Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion
of compensation in income under Section 409A, or the payment of increased taxes, excise taxes or other penalties under Section 409A. The
parties intend this Agreement to be in compliance with Section 409A.

 

(d) All
reimbursements that would be considered nonqualified deferred compensation under Section 409A and provided under this Agreement shall
be made or provided in accordance with the requirements of Section 409A including, where applicable, the requirement that (i) any reimbursement
is for expenses incurred during Executive’s lifetime (or during a shorter period of time specified in this Agreement); (ii) the
amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other
calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following
the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange
for another benefit.

 

    8

     

    

 

(e) If
any payment or benefit Executive would receive under this Agreement, when combined with any other payment or benefit Executive receives
pursuant to a change of control or sale of Company (for purposes of this Section 7(e), a “Payment”) would: (i) constitute
a “parachute payment” within the meaning of Section 280G the Code; and (ii) but for this sentence, be subject to the excise
tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either: (A) the full amount
of such Payment; or (B) such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of
the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes and the Excise Tax,
results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion
of the Payment may be subject to the Excise Tax. With respect to subsection (B), if there is more than one method of reducing the payment
as would result in no portion of the Payment being subject to the Excise Tax, then Executive shall determine which method shall be followed,
provided that if Executive fails to make such determination within thirty (30) days after Company has sent Executive written notice
of the need for such reduction, Company may determine the amount of such reduction in its reasonable discretion. The determination as
to whether and to what extent payments under this Agreement or otherwise are required to be reduced in accordance with this Section 7(e)
shall be made at Company’s expense by an nationally or regionally recognized accounting firm that both Executive and Company agree
upon (the “Accountants”). In the event that any payments under this Agreement or otherwise are required to be reduced
as described in this Section 7(e), the adjustment will be made, first, by reducing the cash severance, if any, due to the Executive pursuant
to Section 4(c) and/or 4(e) of this Agreement, as applicable; and second, if additional reductions are necessary, by reducing the COBRA
continuation benefits due to the Executive under Sections 4(c) of this Agreement, as applicable. In the event that there has been any
underpayment or overpayment under this Agreement or otherwise as determined by the Accountants, the amount of such underpayment or overpayment
shall forthwith be paid to the Executive or refunded to Company, as the case may be, with interest at the applicable federal rate provided
for in Section 7872(f)(2) of the Code.

 

8. Conflicting
Agreements. Company acknowledges that Executive may have obligations to prior employers to safeguard and not use the confidential
information of those companies and related matters.  Company expects Executive to honor such obligations and that Executive has not
taken any documents, electronic information or any other confidential information from any previous employer, and that Executive has returned
(or deleted if so instructed) such information.  Executive also acknowledges that Executive shall not use in the performance of Executive’s
responsibilities for Company any proprietary business or technical information, materials or documents of a former employer, or otherwise
disclose or use any former employer’s confidential information.  

 

    9

     

    

 

9. General.

 

(a) Notices.
Except as otherwise specifically provided herein, any notice required or permitted by this Agreement shall be in writing and shall be
delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier
upon written verification of receipt; or (iii) by certified or registered mail, return receipt requested, upon verification of receipt.

 

		●
                              	Notices
                                            to Executive shall be sent to:

 

The
last known address in Company’s records or such other address as Executive may specify in writing, with a copy to (provided that
delivery of such copy shall not constitute notice to Executive for purposes of this Agreement):

 

Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One
Financial Center

Boston,
MA 02111

Attn:
Laurence P. Naughton, Esq.

Email:
LPNaughton@mintz.com

 

		●
                              	Notices
                                            to Company shall be sent to:

 

Brain
Scientific Inc.

125
Wilbur Place, Suite 170

Bohemia,
NY 11716

Attn:
Board of Directors

 

or
to such other Company representative as Company may specify in writing, with a copy to:

 

[Name]

[Address]

[Address]

Attn:

Email:

 

(b) Modifications;
Amendments; Waivers; Consents. The terms of this Agreement may be modified or amended only by written agreement executed by Executive
and Company. The terms of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed
by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute
a waiver or consent with respect to any other terms of this Agreement, whether or not similar. Each such waiver or consent shall be effective
only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

 

(c) Assignment.
Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of Company’s
business or that aspect of Company’s business in which Executive is principally involved. Executive may not assign Executive’s
rights and obligations under this Agreement without the prior written consent of Company; provided that if Executive should die,
all amounts due following Executive’s death, unless otherwise provided herein, shall be paid in accordance with the terms of this
Agreement to Executive’s devisee, legatee or other designee or, if there is no such designee, to Executive’s estate.

 

(d) Governing
Law; Jurisdiction; Venue. This Agreement shall be governed by and construed in accordance with the substantive laws of the State of
Delaware, without giving effect to any choice or conflict of law provision or rule. The parties (i) hereby irrevocably and unconditionally
submit to the jurisdiction of the state and U.S. federal courts located in the State of Delaware for the purpose of any suit, action or
other proceeding arising out of or based upon this Agreement, (ii) agree not to commence any suit, action or other proceeding arising
out of or based upon this Agreement except in the state or U.S. federal courts located in the State of Delaware, and (iii) hereby waive,
and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not
subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution,
that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper
or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

    10

     

    

 

(e) Headings
and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall
in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

(f) Entire
Agreement. This Agreement, together with the other agreements specifically referenced herein, embodies the entire agreement and understanding
between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings
relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth
in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.

 

(g) Survivorship.
The respective rights and obligations of the parties to this Agreement shall survive the termination of this Agreement or Executive’s
employment hereunder for any reason to the extent necessary for the intended preservation of such rights and obligations. In furtherance
of and not in limitation of the foregoing and for the avoidance of doubt, the provisions of Section 3(g) shall survive any termination
or expiration of this Agreement and any termination of Executive’s employment indefinitely.

 

(h) Representation.
Company represents and warrants that it is fully authorized and empowered to enter into this Agreement and that the performance of its
obligations hereunder shall not violate any agreement between Company and any other person or entity.

 

(i) Severability.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent
permitted by law.

 

(j) Interest.
Any amounts owed to Executive pursuant to this Agreement and that remain unpaid for more than twenty (20) days shall accrue interest at
a rate per annum equal to the lesser of either (i) fifteen percent (15%), compounded daily, or (ii) the maximum rate of interest that
may be collected from Company under applicable law.

 

(j) Original
Agreement. Upon execution of this Agreement by Executive, Company and Piezo, the Original Employment Agreement shall be terminated
and of no further force or effect.

 

(k) Counterparts.
This Agreement may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. For all purposes an electronic signature
shall be treated as an original.

 

[Remainder of page intentionally left blank.]

 

    11

     

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.

 

	HASSAN KOTOB	 	BRAIN SCIENTIFIC INC. 
	 	 	 	 	 	 
	By:	/s/ Hassan Kotob	 	By:	/s/ Bonnie-Jeanne Gerety
	Signature	 	 	Name:  	Bonnie-Jeanne Gerety
	Address: 	 	 	Title:	Chief Financial Officer

 

	FOR PURPOSES OF SECTION 9(j)	 
	 	 
	PIEZO MOTION CORP.	 
	 	 	 	 
	By: 	/s/ Bonnie-Jeanne Gerety	 
	 	Name:	Bonnie-Jeanne Gerety	 
	 	Address: 	Chief Financial Officer	 

 

    12

     

    

 

EXHIBIT A

 

Indemnification Agreement

 

    13

     

    

 

EXHIBIT B

 

Confidentiality and Inventions Assignment Agreement

 

    14

     

    

 

EXHIBIT C

 

FORM OF SEPARATION AND RELEASE AGREEMENT

 

This Separation and Release
Agreement (the “Agreement”), dated as of [●], is entered into between Brain Scientific Inc. (together with its
subsidiaries, affiliates, successors and assigns, the “Company”), and [●] (“Executive”) (Executive,
together with the Company, the “Parties” and each a “Party”).

 

WHEREAS, Executive served
as the Executive Chairman and CEO and member of the Board of Directors (the “Board”) of the Company pursuant to that
certain Executive Employment Agreement dated [●] (the “Employment Agreement”);

 

WHEREAS, Executive’s
employment with the Company and engagement as a member of the Board and any committees thereof ended effective as of [●]; and

 

NOW, THEREFORE, in consideration
of the foregoing and the mutual covenants and undertakings set out below, the Parties hereby agree as follows:

 

		1.	Employment Separation Date. Effective as of [●] (the “Separation Date”),
Executive’s employment with the Company and engagement in any role pursuant thereto, including but not limited to serving on the
Board and any committees thereof, shall end on the Separation Date. This Agreement constitutes the release agreement contemplated by Section
4(d) of the Employment Agreement.

 

		2.	Payments and Benefits.

 

		a.	The Company shall provide Executive with the Accrued Obligations (as such term is defined in the Employment
Agreement).

 

		b.	Provided that this Agreement is signed by Executive in the period of time set forth in Section 4(d) of
the Employment Agreement and not revoked by Executive, the Company shall provide Executive with the Severance Benefits (as such term is
defined in the Employment Agreement) set forth in Section [4(b) / 4(c)] of the Employment Agreement.

 

		c.	The payments referenced in Sections 2(a) and 2(b) shall be made at the applicable time(s) provided for
in the Employment Agreement.

 

		d.	All outstanding equity awards held by Executive shall be treated in accordance with their terms and the
provisions of Section [4(b) / 4(c)] of the Employment Agreement, including with respect to any post-termination exercise periods
for vested stock options.

 

    15

     

    

 

		3.	General Release. Executive does hereby release, remise, acquit and discharge the Company
of and from claims, demands and liabilities: (a) arising out of Executive’s service to the Company; (b) for breach of contract,
breach of covenant of good faith and fair dealing, wrongful discharge, promissory estoppel, infliction of emotional harm, or other tort;
and (c) for violation of applicable labor and employment laws, including the Executive Retirement Income Security Act of 1974, Title VII
of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act, Sections 503 and 504 of the Rehabilitation
Act, the Family and Medical Leave Act, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Equal Pay
Act, the Worker Adjustment and Retraining Notification Act, the Uniformed Services Employment and Re-Employment Act, the Rehabilitation
Act of 1973, and claims arising under the civil rights laws of any federal, state or local jurisdiction; excepting:

 

		a.	rights of Executive under this Agreement;

 

		b.	rights of Executive relating to equity awards held by Executive as of the Separation Date;

 

		c.	the right of Executive to receive COBRA continuation coverage in accordance with applicable law;

 

		d.	rights to indemnification Executive may have (i) under applicable corporate law, (ii) under
the by-laws, certificate of incorporation or similar governing documents of Company, (iii) under a written indemnification agreement with
Company, or (iv) as an insured under any director’s and officer’s liability insurance policy now or previously in force;

 

		e.	claims (i) for benefits under any health, disability, retirement, deferred compensation, life insurance
or other, similar Executive benefit plan or arrangement of the Company and (ii) for earned but unused vacation pay through the Separation
Date in accordance with applicable Company policy; and

 

		f.	claims for the reimbursement of unreimbursed business expenses incurred prior to the Separation Date pursuant
to applicable Company policy; and

 

		g.	any rights that Executive may have as a stockholder (or former stockholder) of Company with respect to
dividend payment rights or payments in respect of shares of Company common stock sold in a merger or other transaction in accordance with
the applicable merger or transaction agreement.

 

Notwithstanding the foregoing, this
Section does not: (A) release the Company from any obligation expressly set forth in this Agreement or from any obligation, including,
without limitation, obligations under the Workers Compensation Act, which as a matter of law cannot be released; (B) prohibit Executive
from filing a charge with the Equal Employment Opportunity Commission (“EEOC”); or (C) prohibit Executive from participating
in an investigation or proceeding by the EEOC or any comparable state or local agency, or providing information or documents to the EEOC
or any comparable state or local agency.

 

		4.	Specific Waiver. Nothing herein shall be deemed to be a waiver of any right or claim or
cause of action which by law Executive is not permitted to waive or release, as to those matters that are expressly outside of the scope
of the release pursuant to Section 3.

 

    16

     

    

 

		5.	Permitted Disclosures. Pursuant to 18 U.S.C. § 1833(b), Executive understands that Executive
shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret of the
Company that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to Executive’s
attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or
other document that is filed under seal in a lawsuit or other proceeding. Executive understands that if Executive files a lawsuit for
retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney
and use the trade secret information in the court proceeding if Executive (x) files any document containing the trade secret under seal,
and (y) does not disclose the trade secret, except pursuant to court order. Nothing in this Agreement, or any other agreement that Executive
has with the Company, is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that
are expressly allowed by such section. Further, nothing in this Agreement or any other agreement that Executive has with the Company shall
prohibit or restrict Executive from (A) making any voluntary disclosure of information or documents concerning possible violations of
law to any governmental agency or legislative body, or any self-regulatory organization, in each case, without advance notice to the Company;
or (B) responding to a valid subpoena, court order or similar legal process; provided, however, that prior to making any
such disclosure pursuant to this Section, Executive shall provide the Company with written notice of the subpoena, court order or similar
legal process sufficiently in advance of such disclosure to afford the Company a reasonable opportunity to challenge the subpoena, court
order or similar legal process.

 

		6.	Complete Agreement. This Agreement constitutes the complete and final agreement between the parties
and supersedes and replaces all prior or contemporaneous agreements, negotiations, or discussions relating to the subject matter of this
Agreement. All provisions and portions of this Agreement are severable. If any provision or portion of this Agreement or the application
of any provision or portion of the Agreement shall be determined to be invalid or unenforceable to any extent or for any reason, all other
provisions and portions of this Agreement shall remain in full force and shall continue to be enforceable to the fullest and greatest
extent permitted by law.

 

		7.	Acceptance; Revocation. Executive acknowledges that he or she has been given a period of twenty-one
(21) days within which to consider this Agreement, unless applicable law requires a longer period, in which case Executive shall
be advised of such longer period and such longer period shall apply. Executive may accept this Agreement at any time within this period
of time by signing the Agreement and returning it to the Company. This Agreement shall not become effective or enforceable until seven
(7) calendar days after Executive signs it. Executive may revoke his or her acceptance of this Agreement at any time within that
seven (7) calendar day period by sending written notice to the Company. Such notice must be received by the Company within the seven
(7) calendar day period in order to be effective and, if so received, would void this Agreement for all purposes. This Agreement
shall become effective on the day following the conclusion of the seven (7) calendar day period.

 

		8.	Governing Law. Except for issues or matters as to which federal law is applicable, this Agreement
shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflicts
of law principles thereof.

 

    17

     

    

 

IN WITNESS WHEREOF, Executive has executed
this Separation and Release Agreement as of the date last set forth below.

 

	EXECUTIVE	 	 
	 	 	 
	 	 	Date: 	 
	 	 	 
	Name:	 	 

 

 

18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]